Development and Technical Validation of an Immunoassay for the Detection of APP669–711 (Aβ−3–40) in Biological Samples

The ratio of amyloid precursor protein (APP)669–711 (Aβ−3–40)/Aβ1–42 in blood plasma was reported to represent a novel Alzheimer’s disease biomarker. Here, we describe the characterization of two antibodies against the N-terminus of Aβ−3–x and the development and “fit-for-purpose” technical validati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of molecular sciences 2020-09, Vol.21 (18), p.6564
Hauptverfasser: Klafki, Hans W., Rieper, Petra, Matzen, Anja, Zampar, Silvia, Wirths, Oliver, Vogelgsang, Jonathan, Osterloh, Dirk, Rohdenburg, Lara, Oberstein, Timo J., Jahn, Olaf, Beyer, Isaak, Lachmann, Ingolf, Knölker, Hans-Joachim, Wiltfang, Jens
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 18
container_start_page 6564
container_title International journal of molecular sciences
container_volume 21
creator Klafki, Hans W.
Rieper, Petra
Matzen, Anja
Zampar, Silvia
Wirths, Oliver
Vogelgsang, Jonathan
Osterloh, Dirk
Rohdenburg, Lara
Oberstein, Timo J.
Jahn, Olaf
Beyer, Isaak
Lachmann, Ingolf
Knölker, Hans-Joachim
Wiltfang, Jens
description The ratio of amyloid precursor protein (APP)669–711 (Aβ−3–40)/Aβ1–42 in blood plasma was reported to represent a novel Alzheimer’s disease biomarker. Here, we describe the characterization of two antibodies against the N-terminus of Aβ−3–x and the development and “fit-for-purpose” technical validation of a sandwich immunoassay for the measurement of Aβ−3–40. Antibody selectivity was assessed by capillary isoelectric focusing immunoassay, Western blot analysis, and immunohistochemistry. The analytical validation addressed assay range, repeatability, specificity, between-run variability, impact of pre-analytical sample handling procedures, assay interference, and analytical spike recoveries. Blood plasma was analyzed after Aβ immunoprecipitation by a two-step immunoassay procedure. Both monoclonal antibodies detected Aβ−3–40 with no appreciable cross reactivity with Aβ1–40 or N-terminally truncated Aβ variants. However, the amyloid precursor protein was also recognized. The immunoassay showed high selectivity for Aβ−3–40 with a quantitative assay range of 22 pg/mL–7.5 ng/mL. Acceptable intermediate imprecision of the complete two-step immunoassay was reached after normalization. In a small clinical sample, the measured Aβ42/Aβ−3–40 and Aβ42/Aβ40 ratios were lower in patients with dementia of the Alzheimer’s type than in other dementias. In summary, the methodological groundwork for further optimization and future studies addressing the Aβ42/Aβ−3–40 ratio as a novel biomarker candidate for Alzheimer’s disease has been set.
doi_str_mv 10.3390/ijms21186564
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7555726</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2442025757</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3044-e981c76784df4a4f669124ddcbc634f1071291af4cc072e39b06f8b9e2dcffa83</originalsourceid><addsrcrecordid>eNpdkUtOHDEQhq0oKDySXQ5gKRsiMcSvtrs3kSaQECSkIPHYWh53mfHIbQ_tbiQWSCyzhpvkIByCk8QEiEhWVaX_01_1qxB6T8k25w355BddZpTWspLiFVqjgrEJIVK9ftGvovWcF4QwzqrmDVrlrKFUEbmGrnbhAkJadhAHbGKLj8HOo7cm4FMTfGsGnyJOrmh4v-vGmEzO5hK71ONhDngXBrDPzPTwUMrm_vpWUYo3p3e_7n_e8DIK8hH7iL_4FNLZH-8j0y0D5LdoxZmQ4d1T3UAn374e73yfHPzY29-ZHkwsJ0JMoKmpVVLVonXCCFeWUCba1s6s5MJRomgJZJywligGvJkR6epZA6y1zpmab6DPj77LcdZBa0vY3gS97H1n-kudjNf_KtHP9Vm60KqqKsVkMdh8MujT-Qh50J3PFkIwEdKYNROCSsoKXdAP_6GLNPaxxHugGGGVqlShth4p26ece3B_j6FEP_xVv_wr_w1HlJc-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2442025757</pqid></control><display><type>article</type><title>Development and Technical Validation of an Immunoassay for the Detection of APP669–711 (Aβ−3–40) in Biological Samples</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Klafki, Hans W. ; Rieper, Petra ; Matzen, Anja ; Zampar, Silvia ; Wirths, Oliver ; Vogelgsang, Jonathan ; Osterloh, Dirk ; Rohdenburg, Lara ; Oberstein, Timo J. ; Jahn, Olaf ; Beyer, Isaak ; Lachmann, Ingolf ; Knölker, Hans-Joachim ; Wiltfang, Jens</creator><creatorcontrib>Klafki, Hans W. ; Rieper, Petra ; Matzen, Anja ; Zampar, Silvia ; Wirths, Oliver ; Vogelgsang, Jonathan ; Osterloh, Dirk ; Rohdenburg, Lara ; Oberstein, Timo J. ; Jahn, Olaf ; Beyer, Isaak ; Lachmann, Ingolf ; Knölker, Hans-Joachim ; Wiltfang, Jens</creatorcontrib><description>The ratio of amyloid precursor protein (APP)669–711 (Aβ−3–40)/Aβ1–42 in blood plasma was reported to represent a novel Alzheimer’s disease biomarker. Here, we describe the characterization of two antibodies against the N-terminus of Aβ−3–x and the development and “fit-for-purpose” technical validation of a sandwich immunoassay for the measurement of Aβ−3–40. Antibody selectivity was assessed by capillary isoelectric focusing immunoassay, Western blot analysis, and immunohistochemistry. The analytical validation addressed assay range, repeatability, specificity, between-run variability, impact of pre-analytical sample handling procedures, assay interference, and analytical spike recoveries. Blood plasma was analyzed after Aβ immunoprecipitation by a two-step immunoassay procedure. Both monoclonal antibodies detected Aβ−3–40 with no appreciable cross reactivity with Aβ1–40 or N-terminally truncated Aβ variants. However, the amyloid precursor protein was also recognized. The immunoassay showed high selectivity for Aβ−3–40 with a quantitative assay range of 22 pg/mL–7.5 ng/mL. Acceptable intermediate imprecision of the complete two-step immunoassay was reached after normalization. In a small clinical sample, the measured Aβ42/Aβ−3–40 and Aβ42/Aβ40 ratios were lower in patients with dementia of the Alzheimer’s type than in other dementias. In summary, the methodological groundwork for further optimization and future studies addressing the Aβ42/Aβ−3–40 ratio as a novel biomarker candidate for Alzheimer’s disease has been set.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms21186564</identifier><identifier>PMID: 32911706</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Alzheimer's disease ; Amyloid precursor protein ; Antibodies ; Binding sites ; Biological properties ; Biomarkers ; Blood plasma ; Brain ; Cell culture ; Dementia ; Dementia disorders ; Immunoassay ; Immunohistochemistry ; Immunoprecipitation ; Isoelectric focusing ; Monoclonal antibodies ; Mutation ; N-Terminus ; Peptides ; Plasma ; Precursors ; Proteins ; Selectivity ; Transgenic animals</subject><ispartof>International journal of molecular sciences, 2020-09, Vol.21 (18), p.6564</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3044-e981c76784df4a4f669124ddcbc634f1071291af4cc072e39b06f8b9e2dcffa83</citedby><cites>FETCH-LOGICAL-c3044-e981c76784df4a4f669124ddcbc634f1071291af4cc072e39b06f8b9e2dcffa83</cites><orcidid>0000-0002-4369-6875 ; 0000-0002-8672-9032 ; 0000-0001-9326-8193 ; 0000-0003-0134-0974 ; 0000-0002-9631-5239 ; 0000-0002-4115-0334 ; 0000-0003-1492-5330 ; 0000-0002-3397-8924</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555726/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555726/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids></links><search><creatorcontrib>Klafki, Hans W.</creatorcontrib><creatorcontrib>Rieper, Petra</creatorcontrib><creatorcontrib>Matzen, Anja</creatorcontrib><creatorcontrib>Zampar, Silvia</creatorcontrib><creatorcontrib>Wirths, Oliver</creatorcontrib><creatorcontrib>Vogelgsang, Jonathan</creatorcontrib><creatorcontrib>Osterloh, Dirk</creatorcontrib><creatorcontrib>Rohdenburg, Lara</creatorcontrib><creatorcontrib>Oberstein, Timo J.</creatorcontrib><creatorcontrib>Jahn, Olaf</creatorcontrib><creatorcontrib>Beyer, Isaak</creatorcontrib><creatorcontrib>Lachmann, Ingolf</creatorcontrib><creatorcontrib>Knölker, Hans-Joachim</creatorcontrib><creatorcontrib>Wiltfang, Jens</creatorcontrib><title>Development and Technical Validation of an Immunoassay for the Detection of APP669–711 (Aβ−3–40) in Biological Samples</title><title>International journal of molecular sciences</title><description>The ratio of amyloid precursor protein (APP)669–711 (Aβ−3–40)/Aβ1–42 in blood plasma was reported to represent a novel Alzheimer’s disease biomarker. Here, we describe the characterization of two antibodies against the N-terminus of Aβ−3–x and the development and “fit-for-purpose” technical validation of a sandwich immunoassay for the measurement of Aβ−3–40. Antibody selectivity was assessed by capillary isoelectric focusing immunoassay, Western blot analysis, and immunohistochemistry. The analytical validation addressed assay range, repeatability, specificity, between-run variability, impact of pre-analytical sample handling procedures, assay interference, and analytical spike recoveries. Blood plasma was analyzed after Aβ immunoprecipitation by a two-step immunoassay procedure. Both monoclonal antibodies detected Aβ−3–40 with no appreciable cross reactivity with Aβ1–40 or N-terminally truncated Aβ variants. However, the amyloid precursor protein was also recognized. The immunoassay showed high selectivity for Aβ−3–40 with a quantitative assay range of 22 pg/mL–7.5 ng/mL. Acceptable intermediate imprecision of the complete two-step immunoassay was reached after normalization. In a small clinical sample, the measured Aβ42/Aβ−3–40 and Aβ42/Aβ40 ratios were lower in patients with dementia of the Alzheimer’s type than in other dementias. In summary, the methodological groundwork for further optimization and future studies addressing the Aβ42/Aβ−3–40 ratio as a novel biomarker candidate for Alzheimer’s disease has been set.</description><subject>Alzheimer's disease</subject><subject>Amyloid precursor protein</subject><subject>Antibodies</subject><subject>Binding sites</subject><subject>Biological properties</subject><subject>Biomarkers</subject><subject>Blood plasma</subject><subject>Brain</subject><subject>Cell culture</subject><subject>Dementia</subject><subject>Dementia disorders</subject><subject>Immunoassay</subject><subject>Immunohistochemistry</subject><subject>Immunoprecipitation</subject><subject>Isoelectric focusing</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>N-Terminus</subject><subject>Peptides</subject><subject>Plasma</subject><subject>Precursors</subject><subject>Proteins</subject><subject>Selectivity</subject><subject>Transgenic animals</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUtOHDEQhq0oKDySXQ5gKRsiMcSvtrs3kSaQECSkIPHYWh53mfHIbQ_tbiQWSCyzhpvkIByCk8QEiEhWVaX_01_1qxB6T8k25w355BddZpTWspLiFVqjgrEJIVK9ftGvovWcF4QwzqrmDVrlrKFUEbmGrnbhAkJadhAHbGKLj8HOo7cm4FMTfGsGnyJOrmh4v-vGmEzO5hK71ONhDngXBrDPzPTwUMrm_vpWUYo3p3e_7n_e8DIK8hH7iL_4FNLZH-8j0y0D5LdoxZmQ4d1T3UAn374e73yfHPzY29-ZHkwsJ0JMoKmpVVLVonXCCFeWUCba1s6s5MJRomgJZJywligGvJkR6epZA6y1zpmab6DPj77LcdZBa0vY3gS97H1n-kudjNf_KtHP9Vm60KqqKsVkMdh8MujT-Qh50J3PFkIwEdKYNROCSsoKXdAP_6GLNPaxxHugGGGVqlShth4p26ece3B_j6FEP_xVv_wr_w1HlJc-</recordid><startdate>20200908</startdate><enddate>20200908</enddate><creator>Klafki, Hans W.</creator><creator>Rieper, Petra</creator><creator>Matzen, Anja</creator><creator>Zampar, Silvia</creator><creator>Wirths, Oliver</creator><creator>Vogelgsang, Jonathan</creator><creator>Osterloh, Dirk</creator><creator>Rohdenburg, Lara</creator><creator>Oberstein, Timo J.</creator><creator>Jahn, Olaf</creator><creator>Beyer, Isaak</creator><creator>Lachmann, Ingolf</creator><creator>Knölker, Hans-Joachim</creator><creator>Wiltfang, Jens</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4369-6875</orcidid><orcidid>https://orcid.org/0000-0002-8672-9032</orcidid><orcidid>https://orcid.org/0000-0001-9326-8193</orcidid><orcidid>https://orcid.org/0000-0003-0134-0974</orcidid><orcidid>https://orcid.org/0000-0002-9631-5239</orcidid><orcidid>https://orcid.org/0000-0002-4115-0334</orcidid><orcidid>https://orcid.org/0000-0003-1492-5330</orcidid><orcidid>https://orcid.org/0000-0002-3397-8924</orcidid></search><sort><creationdate>20200908</creationdate><title>Development and Technical Validation of an Immunoassay for the Detection of APP669–711 (Aβ−3–40) in Biological Samples</title><author>Klafki, Hans W. ; Rieper, Petra ; Matzen, Anja ; Zampar, Silvia ; Wirths, Oliver ; Vogelgsang, Jonathan ; Osterloh, Dirk ; Rohdenburg, Lara ; Oberstein, Timo J. ; Jahn, Olaf ; Beyer, Isaak ; Lachmann, Ingolf ; Knölker, Hans-Joachim ; Wiltfang, Jens</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3044-e981c76784df4a4f669124ddcbc634f1071291af4cc072e39b06f8b9e2dcffa83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alzheimer's disease</topic><topic>Amyloid precursor protein</topic><topic>Antibodies</topic><topic>Binding sites</topic><topic>Biological properties</topic><topic>Biomarkers</topic><topic>Blood plasma</topic><topic>Brain</topic><topic>Cell culture</topic><topic>Dementia</topic><topic>Dementia disorders</topic><topic>Immunoassay</topic><topic>Immunohistochemistry</topic><topic>Immunoprecipitation</topic><topic>Isoelectric focusing</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>N-Terminus</topic><topic>Peptides</topic><topic>Plasma</topic><topic>Precursors</topic><topic>Proteins</topic><topic>Selectivity</topic><topic>Transgenic animals</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Klafki, Hans W.</creatorcontrib><creatorcontrib>Rieper, Petra</creatorcontrib><creatorcontrib>Matzen, Anja</creatorcontrib><creatorcontrib>Zampar, Silvia</creatorcontrib><creatorcontrib>Wirths, Oliver</creatorcontrib><creatorcontrib>Vogelgsang, Jonathan</creatorcontrib><creatorcontrib>Osterloh, Dirk</creatorcontrib><creatorcontrib>Rohdenburg, Lara</creatorcontrib><creatorcontrib>Oberstein, Timo J.</creatorcontrib><creatorcontrib>Jahn, Olaf</creatorcontrib><creatorcontrib>Beyer, Isaak</creatorcontrib><creatorcontrib>Lachmann, Ingolf</creatorcontrib><creatorcontrib>Knölker, Hans-Joachim</creatorcontrib><creatorcontrib>Wiltfang, Jens</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Klafki, Hans W.</au><au>Rieper, Petra</au><au>Matzen, Anja</au><au>Zampar, Silvia</au><au>Wirths, Oliver</au><au>Vogelgsang, Jonathan</au><au>Osterloh, Dirk</au><au>Rohdenburg, Lara</au><au>Oberstein, Timo J.</au><au>Jahn, Olaf</au><au>Beyer, Isaak</au><au>Lachmann, Ingolf</au><au>Knölker, Hans-Joachim</au><au>Wiltfang, Jens</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and Technical Validation of an Immunoassay for the Detection of APP669–711 (Aβ−3–40) in Biological Samples</atitle><jtitle>International journal of molecular sciences</jtitle><date>2020-09-08</date><risdate>2020</risdate><volume>21</volume><issue>18</issue><spage>6564</spage><pages>6564-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>The ratio of amyloid precursor protein (APP)669–711 (Aβ−3–40)/Aβ1–42 in blood plasma was reported to represent a novel Alzheimer’s disease biomarker. Here, we describe the characterization of two antibodies against the N-terminus of Aβ−3–x and the development and “fit-for-purpose” technical validation of a sandwich immunoassay for the measurement of Aβ−3–40. Antibody selectivity was assessed by capillary isoelectric focusing immunoassay, Western blot analysis, and immunohistochemistry. The analytical validation addressed assay range, repeatability, specificity, between-run variability, impact of pre-analytical sample handling procedures, assay interference, and analytical spike recoveries. Blood plasma was analyzed after Aβ immunoprecipitation by a two-step immunoassay procedure. Both monoclonal antibodies detected Aβ−3–40 with no appreciable cross reactivity with Aβ1–40 or N-terminally truncated Aβ variants. However, the amyloid precursor protein was also recognized. The immunoassay showed high selectivity for Aβ−3–40 with a quantitative assay range of 22 pg/mL–7.5 ng/mL. Acceptable intermediate imprecision of the complete two-step immunoassay was reached after normalization. In a small clinical sample, the measured Aβ42/Aβ−3–40 and Aβ42/Aβ40 ratios were lower in patients with dementia of the Alzheimer’s type than in other dementias. In summary, the methodological groundwork for further optimization and future studies addressing the Aβ42/Aβ−3–40 ratio as a novel biomarker candidate for Alzheimer’s disease has been set.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>32911706</pmid><doi>10.3390/ijms21186564</doi><orcidid>https://orcid.org/0000-0002-4369-6875</orcidid><orcidid>https://orcid.org/0000-0002-8672-9032</orcidid><orcidid>https://orcid.org/0000-0001-9326-8193</orcidid><orcidid>https://orcid.org/0000-0003-0134-0974</orcidid><orcidid>https://orcid.org/0000-0002-9631-5239</orcidid><orcidid>https://orcid.org/0000-0002-4115-0334</orcidid><orcidid>https://orcid.org/0000-0003-1492-5330</orcidid><orcidid>https://orcid.org/0000-0002-3397-8924</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2020-09, Vol.21 (18), p.6564
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7555726
source MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Alzheimer's disease
Amyloid precursor protein
Antibodies
Binding sites
Biological properties
Biomarkers
Blood plasma
Brain
Cell culture
Dementia
Dementia disorders
Immunoassay
Immunohistochemistry
Immunoprecipitation
Isoelectric focusing
Monoclonal antibodies
Mutation
N-Terminus
Peptides
Plasma
Precursors
Proteins
Selectivity
Transgenic animals
title Development and Technical Validation of an Immunoassay for the Detection of APP669–711 (Aβ−3–40) in Biological Samples
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T18%3A10%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20Technical%20Validation%20of%20an%20Immunoassay%20for%20the%20Detection%20of%20APP669%E2%80%93711%20(A%CE%B2%E2%88%923%E2%80%9340)%20in%20Biological%20Samples&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Klafki,%20Hans%20W.&rft.date=2020-09-08&rft.volume=21&rft.issue=18&rft.spage=6564&rft.pages=6564-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms21186564&rft_dat=%3Cproquest_pubme%3E2442025757%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2442025757&rft_id=info:pmid/32911706&rfr_iscdi=true